Coccidioidomycosis

Management of coccidioidomycosis first involves recognizing that a coccidioidal infection exists, defining the extent of infection, and identifying host factors that predispose to disease severity. After these assessments, patients with localized acute pulmonary infections and no risk factors for co...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2005-11, Vol.41 (9), p.1217-1223
Main Authors: Galgiani, John N., Ampel, Neil M., Blair, Janis E., Catanzaro, Antonino, Johnson, Royce H., Stevens, David A., Williams, Paul L.
Format: Article
Language:English
Subjects:
Antifungals
Azoles
Biological and medical sciences
Coccidioidomycosis
Coccidioidomycosis - diagnosis
Coccidioidomycosis - therapy
Dosage
Drug therapy
Fungal infections
Human mycoses
Humans
IDSA Guidelines
Immunology
Infections
Infectious diseases
Lesions
Medical sciences
Medical treatment
Mycoses
Pneumonia
Recommendations
Tropical mycoses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of coccidioidomycosis first involves recognizing that a coccidioidal infection exists, defining the extent of infection, and identifying host factors that predispose to disease severity. After these assessments, patients with localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or who are at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal drug therapy, surgical debridement, or a combination of both. Azole antifungals, primarily fluconazole and itraconazole, have replaced amphotericin B as initial therapy for most chronic pulmonary or disseminated infections. Amphotericin B is now usually reserved for patients with respiratory failure due to infection with Coccidioides species, those with rapidly progressive coccidioidal infections, or women during pregnancy. Therapy often ranges from many months to years in duration, and in some patients, lifelong suppressive therapy is needed to prevent relapses. [PUBLICATION ABSTRACT]
ISSN:1058-4838
1537-6591
DOI:10.1086/496991